A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)
Conditions: Anemia, Sickle Cell Interventions: Drug: HBI-002 Sponsors: Hillhurst Biopharmaceuticals, Inc.; National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Anemia | Carbon Monoxide Poisoning | Cardiology | Heart | Research | Sickle Cell Anemia | Study